Cell and Gene Therapy Market

1
Global Cell and Gene Therapy Market Is Estimated
To Witness High Growth Owing To Increasing
Investment in Research and Development Activities
Growing Demand for Personalized Medicine The
global Cell and Gene Therapy market is estimated
to be valued at US 22.7 billion in 2023 and is
expected to exhibit a CAGR of 28.7 over the
forecast period 2023-2030. A) Market Overview
Cell and gene therapy involves the use of
genetic material, such as DNA or RNA, to treat
and potentially cure diseases by repairing or
replacing faulty genes. These innovative
therapies offer promising treatment options for
a wide range of diseases, including cancer,
genetic disorders, neurodegenerative diseases,
and autoimmune disorders. The market is
witnessing significant growth due to the
increasing investment in research and
development activities and the growing demand for
personalized medicine. Advanced technologies,
such as CRISPR-Cas9, have revolutionized the
field of cell and gene therapy, making it more
efficient and precise. B) Market Dynamics The
market dynamics of the cell and gene therapy
market are driven by two key factors increasing
investment in research and development
activities, and the growing demand for
personalized medicine. 1. Increasing Investment
in Research and Development Activities
Pharmaceutical companies, research institutions,
and government organizations are investing
heavily in cell and gene therapy research,
leading to advancements in the field. This
investment is driven by the potential of these
therapies to provide targeted and more effective
treatment options compared to traditional
treatments. For example, Novartis and Kite Pharma
received approval for their CAR-T cell
therapies, which are used to treat certain types
of blood cancers. 2. Growing Demand for
Personalized Medicine The demand for
personalized medicine is increasing as patients
are seeking treatments tailored to their
specific genetic makeup. Cell and gene therapy
offer personalized treatment options by targeting
the underlying genetic causes of diseases. This
approach has the potential to provide better
outcomes and reduce the risk of adverse effects
compared to traditional treatments. For example,
Luxturna, developed by Spark Therapeutics, is
the first gene therapy approved by the FDA for
the treatment of a specific inherited retinal
disease. C) Segment Analysis The cell and gene
therapy market can be segmented based on therapy
type, application, and region. Gene therapy is
expected to dominate the market due to its wide
range of applications and potential for
personalized treatment. Within gene therapy, ex
vivo therapy is expected to dominate the market
as it allows for the modification of cells
outside the body before being reintroduced. This
approach provides better control and safety for
the patients.
2
D) PEST Analysis Political The regulatory
landscape plays a significant role in the
development and commercialization of cell and
gene therapies. The approval process for these
therapies varies across different regions, and
companies need to navigate through complex
regulations to bring their products to market.
Economic The cell and gene therapy market is
driven by economic factors such as healthcare
expenditure, reimbursement policies, and the
availability of funding for research and
development activities. The increasing
healthcare expenditure and favorable
reimbursement policies in developed regions are
driving market growth. Social The acceptance
of cell and gene therapy among patients and
healthcare professionals is crucial for market
growth. Awareness about these therapies and their
potential benefits is increasing, leading to a
growing acceptance and demand for personalized
treatments. Technological Technological
advancements, such as gene editing tools like
CRISPR-Cas9, are revolutionizing the field of
cell and gene therapy. These advancements are
making the development and manufacturing of
these therapies more efficient and
cost-effective. E) Key Takeaways - The global
cell and gene therapy market is expected to
witness high growth, exhibiting a CAGR of 28.7
over the forecast period, due to increasing
investment in research and development activities
and the growing demand for personalized
medicine. - North America is the fastest-growing
and dominating region in the cell and gene
therapy market, driven by the presence of key
market players, favorable reimbursement policies,
and advanced healthcare infrastructure. - Key
players operating in the global cell and gene
therapy market include Novartis International AG,
Pfizer, Inc., Sanofi S.A., Amgen, Inc.,
Regeneron Pharmaceuticals, Inc., and Bluebird
Bio, Inc.